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Abstract. Starting from 3-decladinosyl-9a,11-cyclic carbamates of 15 membered azalide, strained tricyclic 
aglycone derivatives were prepared. The bridging 5-membered hemiketal ring was obtained by intramole-
cular ketalization of intermediary 3-keto derivative, whereas 5-membered ether derivatives were obtained 
by intramolecular Williamson-type displacement. In case of 12-O-alkyl derivatives complete diastereos-
lective formation of ethers was observed, while unsubstituted compound gave diastereomeric mixture. 
NMR analysis was used to confirm the structures of new tricyclic azalide compounds. 
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INTRODUCTION 
The macrolides belong to the polyketide class of natural 
products. They are a group of antibiotics, the antimi-
crobial activity of which stems from the presence of a 
macrocyclic lactone ring to which one or more deoxy 
sugars, usually cladinose and desozamine, are attached.1 
Clarithromycin2−6 and azithromycin7 (Figure 1), the se-
cond generation of macrolides, have been clinically 
used. Azithromycin, a 15-membered azalide is characte-
rized with enhanced antibacterial profile and improved 
pharmacokinetic properties in comparison to 14-mem-
bered erythromycin and clarithromycin.8 
Other biological effects of macrolide, beside anti-
bacterial one, have been reported in the last decade. 
Azithromycin proved effective in treatment of malaria,9 
while some other macrolide derivatives exhibited anti-
inflammatory,10 anticancer effect11 and effect on gastro-
intestinal motility.12  
The cladinose sugar on position 3 was considered 
for many years as an essential part of macrolide mole-
cule for antibacterial activity. However, some new dis-
covered molecules without L-cladinose proved effec-
tive, obviating the known mechanisms of resistance. 
The most known are decladinosyl macrolides that have 
3-keto,13,14 3-O-acyl15 and 2,3-anhydro16,17 functionality. 
Recently, we described a series of bicyclic 15-
membered azalides18 with moderate antibacterial activi-
ty. Herein, we report the synthesis and structural proper-
ties of novel 15-membered azalides with a unique tri-
cyclic structure in their aglycone moiety, broadening the 




IR spectra were recorded in KBr pastilles on a Nicolet 
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Figure 1. Chemical structures of clinically used macrolides. 
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form LCZ and LCQ Deca for ESI-MS. 1H and 13C NMR 
spectra were measured with a Varian Unity Inova 600, 
Bruker Advance DRX 500 and Bruker Advance DPX 
300 spectrometra in CDCl3 using trimethylsilan as in-
ternal standard. 
Compounds 1−6 were prepared as already de-
scribed.18 
Synthesis of 3-decladinosyl-3,6-hemiketal derivatives 
3-Decladinosyl-9-deoxo-9-dihydro-9a-aza-9a-homoery-
thromycin A 3,6-hemiketal 9a,11-cyclic carbamate 7 
To a solution of 2'-O-acetyl-3-decladinosyl-9-deoxo-9-
dihydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic 
carbamate 4 (2.83 g, 4.39 mmol) in CH2Cl2 (50 ml) 
DMSO (4.08 ml, 5.32 mmol) and N,N-dimethyl-
aminopropyl-ethyl-carbodiimid (5.05 g, 26.34 mmol) 
were added. The reaction mixture was cooled to 15 ºC. 
Keeping the temperature constant, solution of pyridini-
um trifluoroacetate (5.01 g, 20.21 mmol) in CH2Cl2 (10 
ml) was dropwise added to the reaction mixture during 
30 minutes. The reaction mixture was stirred from 15 ºC 
to room temperature for additional 2 hours. To the reac-
tion mixture saturated aqueous solution of NaCl (25 ml) 
was added and the pH adjusted to 9.5. The layers were 
separated and the aqueous layer was extracted two more 
times with CH2Cl2. Combined organic extracts were 
rinsed with brine, std. NaHCO3 and water, dried over 
K2CO3 and evaporated yielding 2.5 g of the 2'-acety-
lated product. The obtained product was dissolved in 
MeOH (50 ml) and the solution was stirred for 24 hours 
at room temperature. Solvent was evaporated and the 
residue (2.26 g) purified by low pressure chromatogra-
phy on a silica gel column using the system 
CH2Cl2/MeOH/NH4OH (90:9:1.5). Evaporation of chro-
matographically homogenous fractions yielded the 
product 7 (2.06 g, 88 %). 
Under the same conditions, starting from 2'-O-
acetyl-3-decladinosyl-12-O-methyl-9-deoxo-9-dihydro-
9a-aza-9a-homoerythromycin A 9a,11-cyclic carbamate 
5 and 2'-O-acetyl-3-decladinosyl-12-O-ethyl-9-deoxo-9-
dihydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic 
carbamate 6, the corresponding 3-decladinosyl-12-O-
methyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythromy-
cin A 3,6-hemiketal 9a,11-cyclic carbamate 8 and 3-
decladinosyl-12-O-ethyl-9-deoxo-9-dihydro-9a-aza-9a-
homoerythromycin A 3,6-hemiketal 9a,11-cyclic car-
bamate 9 were prepared. Results and physicochemical 
data for 3,6-hemiketal derivatives are given in Table 1. 
3-Decladinosyl-3-keto-6-O-metil-9-deoxo-9-dihydro-9a-
aza-9a-homoerythromycin A 9a,11-cyclic carbamate 20 
Compound 20 was obtained as a white solid (0.10 g, 60 
%) starting from 2'-O-acetyl-3-decladinosyl-6-O-metil-
9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A 
9a,11-cyclic carbamate 19 applying the same reaction 
conditions as described for preparation of compounds 7, 
8 and 9. ESI-MS m/z: 615.6 (M+H)+; IR (KBr) 
νmax/cm
−1: 3430, 2974, 2927, 1734, 1637, 1560, 1458, 
1428, 1374, 1250, 1187, 1168, 1104, 1082, 1047, 1009, 
970, 797, 765, 676; 1H NMR (500 MHz, CDCl3) /ppm: 
5.10 (H-13), 4.40 (H-1'), 4.36 (H-5), 4.21 (H-11), 3.84 
(H-2), 3.57 (H-5'), 3.53 (H-9a), 3.47 (H-10), 3.32 (6-O-
Me), 3.26 (H-2'), 3.20 (H-4), 2.50 (H-3'), 2.31 (H-8), 
2.31 (H-9b), 2.28 (3'-NMe2), 1.92 (H-14a), 1.67 (H-4'a), 
1.52 (H-14b), 1.47 (H-7a), 1.30 (6-Me), 1.30 (10-Me), 
1.25 (2-Me), 1.24 (5'-Me), 1.23 (H-4'b), 1.22 (12-Me), 
1.14 (H-7b), 1.02 (4-Me), 1.00 (8-Me), 0.93 (14-Me); 
13C NMR (75 MHz, CDCl3) /ppm: 207.1 (C-3), 171.1 
(C-1), 156.5 (9a,11-C=O), 103.0 (C-1'), 79.9 (C-6), 79.5 
(C-13), 78.0 (C-11), 76.2 (C-5), 73.7 (C-12), 70.8 (C-
2'), 69.7 (C-5'), 65.9 (C-3'), 58.4 (C-10), 51.1 (C-2), 
50.9 (C-4), 50.6 (6-O-Me), 49.5 (C-9), 39.9 (3'-NMe2), 
36.6 (C-7), 27.9 (C-4'), 25.3 (C-8), 20.7 (5'-Me), 20.4 
(6-Me), 20.2 (8-Me), 20.0 (C-14), 15.8 (2-Me), 15.2 
(12-Me), 13.4 (10-Me), 10.0 (14-Me), 7.9 (4-Me). 
Synthesis of 2'-O-acetyl-3-decladinosyl-3-O-mesyl 
derivatives 
2'-O-Acetyl-3-decladinosyl-3-O-mesyl-9-deoxo-9-
dihydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic 
carbamate 10 
To a solution of 2'-O-acetyl-3-decladinosyl-9-deoxo-9-
dihydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic 
carbamate 4 (1.21 g, 1.88 mmol) in pyridine (60 ml) 
methanesulfonic anhydride (1.18 g, 6.75 mmol) was 
added and the reaction mixture was stirred at room 
temperature for 4 hours. The solvent was evaporated 
and the residue was dissolved in CH2Cl2 (50 ml). Satu-
rated aqueous solution of NaHCO3 (50 ml) was added, 
the layers were separated and the aqueous layer was 
extracted two more times with CH2Cl2. Combined or-
ganic extracts were rinsed with NaHCO3 and brine, 
dried over K2CO3 and evaporated yielding 1.8 g of 
crude product 10. 
Starting from 2'-O-acetyl-3-decladinosyl-12-O-
methyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythromy-
cin A 9a,11-cyclic carbamate 5, 2'-O-acetyl-3-de-
cladinosyl-12-O-ethyl-9-deoxo-9-dihydro-9a-aza-9a-ho-
moerythro-mycin A 9a,11-cyclic carbamate 6 and 2'-O-
acetyl-3-decladinosyl-6-O-methyl-9-deoxo-9-dihy-dro-
9a-aza-9a-homoerythromycin A 9a,11-cyclic carba-
mate 19 in the same manner as described for compound 
10, crude 2'-O-acetyl-3-decladinosyl-3-O-mesyl-12-O-
methyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythromy-
cin A 9a,11-cyclic carbamate 11, 2'-O-acetyl-3-decla-
dinosyl-3-O-mesyl-12-O-ethyl-9-deoxo-9-dihydro-9a-
aza-9a-homoerythro-mycin A 9a,11-cyclic carbamate 
12 and 2'-O-acetyl-3-decladinosyl-3-O-mesyl-6-O-
methyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythromy-
cin A 9a,11-cyclic carbamate 21 were obtained. Physi- 
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cochemical data for 3-decladinosyl-3-O-mesyl deriva-
tives are given in Table 2. 
Synthesis of 3-decladinosyl-3,6-cyclic ether derivati-
ves 
3-Decladinosyl-9-deoxo-9-dihydro-9a-aza-9a-homoery-
thromycin A 3,6-cyclic ether 9a,11-cyclic carbamate 13 
To a solution of 2'-O-acetyl-3-decladi To a solution of 
2'-O-acetyl-3-decladinosyl-3-O-mesyl-9-deoxo-9-dihy-
dro-9a-aza-9a-homoerythromycin A 9a,11-cyclic car-
bamate 10 (1.00 g, 1.38 mmol) in DMF/THF (30 ml/10 
ml) 60 % suspension of NaH in mineral oil (0.22 g, 5.53 
mmol) was added and the reaction mixture was stirred 
at 0 C for 4 hours. The reaction mixture was poured 
into saturated aqueous solution of NaHCO3 (50 ml), 
EtOAc (50 ml) was added and the layers were sepa-
rated. The aqueous layer was extracted two more times 
with EtOAc. Combined organic extracts were rinsed 
with std. NaHCO3 and brine, dried over K2CO3 and 
evaporated yielding 0.73 g of product. The obtained 
product was dissolved in MeOH (60 ml) and then stirred 
for 24 hours at room temperature. The solvent was eva-
porated and the crude product was purified by chroma-
tography on a silica gel column using the system 
CH2Cl2/MeOH/NH4OH (90:3:0.5). First-running (faster) 
diasteromer 13a (Rf = 0.28) and slower diasteromer 13b 
(Rf = 0.26) were separated. 
Under the same conditions, starting from 2'-O-
acetyl-3-decladinosyl-3-O-mesyl-12-O-methyl-9-deoxo-
9-dihydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic 
carbamate 11 and 2'-O-acetyl-3-decladinosyl-3-O-
mesyl-12-O-ethyl-9-deoxo-9-dihydro-9a-aza-9a-homoe-
rythromycin A 9a,11-cyclic carbamate 12, the corres-
ponding 3-decladinosyl-12-O-methyl-9-deoxo-9-dihy-
dro-9a-aza-9a-homoerythromycin A 3,6-cyclic ether 
9a,11-cyclic carbamate 14 and 3-decladinosyl-12-O-
ethyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin 
A 3,6- cyclic ether 9a,11-cyclic carbamate 15 were 
prepared. Physicochemical data of 3,6-cyclic ether de-
rivatives are given in Table 3. 
3-Decladinosyl-2,3-anhydro-6-O-methyl-9-deoxo-9-
dihydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic 
carbamate 22 
Compound 22 was obtained as a white solid (0.10 g, 62 
%) starting from 2'-O-acetyl-3-decladinosyl-3-O-mesyl-
6-O-methyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythro-
mycin A 9a,11-cyclic carbamate 21 applying the same 
reaction conditions as described for preparation of com-
pounds 13a, 13b, 14 and 15. ES-MS m/z: 585.7 
(M+H)+; IR (KBr) νmax/cm
−1: 3450, 2971, 2928, 1740, 
1639, 1461, 1383, 1350, 1255, 1170, 1114, 1077, 1044, 
999, 974, 945, 912, 864, 767, 635; 1H NMR (500 MHz, 
CDCl3) /ppm: 6.42 (H-2), 5.22 (H-3), 5.13 (H-13), 
4.44 (H-1'), 4.26 (H-11), 3.59 (H-5'), 3.50 (H-9a), 3.41 
(H-10), 3.36 (H-5), 3.30 (6-O-Me), 3.29 (H-2'), 2.57 (H-
4), 2.52 (H-3'), 2.33 (H-8), 2.28 (H-9b), 2.26 (3'-NMe2), 
1.90 (H-14a), 1.61 (H-4'a), 1.52 (H-14b), 1.41 (H-7a), 
1.30 (6-Me), 1.28 (10-Me), 1.26 (2-Me), 1.24 (5'-Me), 
1.23 (H-4'b), 1.20 (12-Me), 1.14 (H-7b), 1.00 (4-Me), 
0.98 (8-Me), 0.88 (14-Me); 13C NMR (75 MHz, CDCl3) 
/ppm: 169.9 (C-1), 156.1 (9a,11-C=O), 146.8 (C-2), 
122.9 (C-3), 104.0 (C-1'), 83.6 (C-5), 79.7 (C-6), 78.0 
(C-11), 75.6 (C-13), 73.1 (C-12), 70.1 (C-2'), 69.4 (C-
5'), 65.6 (C-3'), 58.4 (C-10), 50.7 (6-O-Me), 49.0 (C-9), 
45.4 (C-4), 39.6 (3'-NMe2), 36.6 (C-7), 27.9 (C-4'), 25.3 
(C-8), 20.9 (5'-Me), 20.4 (6-Me), 20.0 (8-Me), 20.0 (C-
14), 15.7 (2-Me), 15.2 (12-Me), 13.2 (10-Me), 10.0 (14-
Me), 7.6 (4-Me). 
6-O-Methyl-9-deoxo-9-dihydro-9a-aza-9a-homoery-
thromycin A 9a,11-cyclic carbamate 17 
To a solution of 6-O-methyl-9-deoxo-9-dihydro-9a-aza-
9a-homoerythromycin A 16 (1.12 g, 1.50 mmol) in 
toluene (10 ml) NaHCO3 (5.02 g, 59.76 mmol) was 
added. The reaction mixture was heated to reflux and 50 
% solution of benzyloxycarbonyl chloride in toluene 
(7.5 ml, 22.43 mmol) was added dropwise over 1 hour 
and stirred for additional 3 hours at reflux. The reaction 
mixture was cooled, NaHCO3 filtered and the suspen-
sion washed with HCl, 0.25 mol dm−3 (2 × 10 ml). The 
organic layer was washed with brine (3 × 15 ml), dried 
over K2CO3 and evaporated yielding crude oily inter-
mediate. The oily residue (1.20 g, 1.06 mmol) was dis-
solved in DMF (15 ml), cooled to 0−5 C and then 60 % 
suspension of NAH in mineral oil (0.04 g, 1.00 mmol) 
was added portionwise during 1 hour. The reaction 
mixture was stirred for additional 3 hours at 0−5 C. To 
the suspension saturated aqueous solution of NaHCO3 
(15 ml) and EtOAc (15 ml) were added and the layers 
were separated. The organic layer was washed with 
brine (3 × 15 ml), dried over K2CO3 and evaporated 
yielding crude oily product. To the solution of such 
crude product (2.2 g) in 96 % EtOH (20 ml) 10 % Pd/C 
(1.0 g) was added, whereas pH was adjusted to 5−6 by 
acetate buffer. The reaction mixture was stirred in Parr 
vehicle at hydrogen pressure (15 barr) at r.t. for 24 
hours. Afterwards 36 % aqueous solution of formalde-
hyde (2 ml) was added and at the same hydrogen pres-
sure the reaction was stirred for additional 4 hours. The 
catalyst was filtered, and the solvent evaporated under 
reduced pressure. The residue was diluted with water, 
the pH value adjusted to 9−10 and then extracted with 
CH2Cl2 (3 × 20 ml). Collected organic extracts were 
washed with brine (3 × 20 ml), dried over K2CO3 and 
evaporated yielding crude product. Purification by high 
pressure column chromatography using the system 
CH2Cl2/MeOH/NH4OH (90:3:0.3) yielded product 17 
(0.6 g, 73 %) ES-MS m/z: 775.7 (M+H)+; IR (KBr) 
νmax/cm
−1: 3450, 2973, 2939, 2760, 1747, 1640, 1452,  
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1415, 1381, 1251, 1167, 1110, 1053, 1000, 956, 894, 
834, 766, 676, 636; 1H NMR (500 MHz, CDCl3) /ppm: 
5.11 (H-13), 4.88 (H-1''), 4.45 (H-1'), 4.32 (H-11), 4.15 
(H-3), 4.06 (H-5''), 3.66 (H-10), 3.80 (H-5), 3.43 (H-5'), 
3.46 (H-9a), 3.31 (3''-O-Me), 3.30 (6-O-Me), 3.27 (H-
2'), 3.04 (H-4''), 2.86 (H-2), 2.52 (H-3'), 2.40 (H-9b), 
2.36 (H-2''a), 2.32 (3'-NMe2), 2.32 (H-8), 2.20 (H-4), 
1.70 (H-4'a), 1.69 (H-14a), 1.60 (H-2''b), 1.54 (H-14b), 
1.34 (6-Me), 1.31 (H-4'b), 1.30 (10-Me), 1.30 (5''-Me), 
1.28 (2-Me), 1.25 (5'-Me), 1.24 (3''-Me), 1.15 (12-Me), 
1.07 (4-Me), 0.93 (8-Me), 0.88 (15-Me); 13C NMR (75 
MHz, CDCl3) /ppm: 174.4 (C-1), 156.5 (9a,11-CO), 
103.2 (C-1'), 96.3 (C-1''), 80.5 (C-3), 79.8 (C-11), 79.6 
(C-5), 79.2 (C-6), 77.9 (C-4''), 75.0 (C-12), 74.5 (C-13), 
73.1 (C-3''), 71.2 (C-2'), 69.0 (C-5'), 66.1 (C-5''), 65.9 
(C-3'), 57.9 (C-10), 51.9 (6-O-Me), 49.6 (C-9), 49.6 (3''-
O-Me), 45.1 (C-2), 40.6 (3'-NMe2), 39.0 (C-4), 37.6 (C-
7), 35.4 (C-2''), 28.0 (C-4'), 26.1 (C-8), 21.9 (5'-Me), 
21.8 (3''-Me), 21.4 (8-Me), 20.8 (C-14), 20.0 (6-Me), 
18.6 (5''-Me), 16.3 (2-Me), 14.2 (12-Me), 13.9 (10-Me), 
10.7 (15-Me), 9.3 (4-Me). 
3-Decladinosyl-6-O-methyl-9-deoxo-9-dihydro-9a-aza-
9a-homoerythromycin A 9a,11-cyclic carbamate 18 
To a solution of compound 17 (0.60 g, 0.77 mmol) in 96 
% ethanol (20 ml) 0.25 mol dm−3 hydrochloric acid (≈ 
50 ml) was added (pH ≈ 1) and the reaction mixture was 
stirred for 24 hours at r.t. Ethanol was evaporated, 
CH2Cl2 (20 ml) was added and the layers were sepa-
rated. The pH value of the water layer was adjusted to 
9.5 and then water was extracted with CH2Cl2 (3 × 30 
ml). Combined organic extracts at pH 9.5 were rinsed 
with brine, dried over K2CO3 and evaporated yielding 
product 18 (0.38 g, 80 %) FAB-MS m/z: 617.6 (M+H)+; 
IR (KBr) νmax/cm
−1: 3440, 2974, 2933, 2880, 2786, 
1747, 1636, 1454, 1416, 1381, 1250, 1217, 1165, 1111, 
1068, 1044, 1000, 947, 915, 899, 772; 1H NMR (500 
MHz, CDCl3) /ppm: 5.11 (H-13), 4.42 (H-1'), 4.26 (H-
11), 3.78 (H-3), 3.59 (H-5'), 3.56 (H-5), 3.53 (H-9a), 
3.47 (H-10), 3.32 (6-O-Me), 3.26 (H-2'), 2.58 (H-2), 
2.50 (H-3'), 2.33 (H-8), 2.30 (H-9b), 2.26 (3'-NMe2), 
2.12 (H-4), 1.90 (H-14a), 1.66 (H-4'a), 1.52 (H-14b), 
1.49 (H-7a), 1.30 (6-Me), 1.30 (10-Me), 1.27 (2-Me), 
1.26 (5'-Me), 1.23 (H-4'b), 1.22 (12-Me), 1.10 (H-7b), 
1.01 (4-Me), 1.01 (8-Me), 0.90 (15-Me); 13C NMR (75 
MHz, CDCl3) /ppm: 174.7 (C-1), 156.4 (9a,11-C=O), 
106.0 (C-1'), 93.6 (C-5), 79.5 (C-6), 78.0 (C-11), 77.6 
(C-3), 75.6 (C-13), 73.7 (C-12), 70.2 (C-2'), 69.7 (C-5'), 
65.1 (C-3'), 58.4 (C-10), 51.7 (6-O-Me), 49.5 (C-9), 
44.4 (C-2), 39.9 (3'-NMe2), 36.6 (C-7), 36.,9 (C-4), 27.9 
(C-4'), 25.3 (C-8), 20.9 (5'-Me), 20.4 (6-Me), 20.0 (8-
Me), 20.0 (C-14), 15.7 (2-Me), 15.2 (12-Me), 13.2 (10-
Me), 10.0 (15-Me), 7.6 (4-Me). 
 
2'-O-Acetyl-3-decladinosyl-6-O-methyl-9-deoxo-9-
dihydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic 
carbamate 19 
To a solution of compound 18 (0.38 g, 0.62 mmol) in 
CH2Cl2 (20 ml), NaHCO3 (0.26 g, 3.10 mmol) and acet-
ic acid anhydride (0.10 ml, 1.06 mmol) were added and 
the reaction mixture was stirred for 4 hours at room 
temperature. When TLC indicates complete conversion 
saturated NaHCO3 solution was added to the reaction 
mixture, the layers were separated and the aqueous one 
was extracted with CH2Cl2. The combined organic ex-
tracts were rinsed with saturated aqueous NaHCO3 solu-
tion, dried over K2CO3 and evaporated yielding product 
19 (0.38 g, 93 %). FAB-MS m/z: 659.7 (M+H)+; IR 
(KBr) νmax/cm
−1: 3459, 2974, 2937, 2878, 2788, 1747, 
1574, 1454, 1415, 1376, 1247, 1164, 1114, 1066, 1001, 
947, 897, 813, 769, 667. 
 
RESULTS AND DISCUSSION 
We reported19 that 9a-benzyloxycarbonyl-9a-aza-9-
deoxo-9-dihydro-9a-homoerythromycin A could be 
converted into 9a,11-cyclic carbamate by base-mediated 
intramolecular interaction between 9a-benzyloxycar-
bonyl and 11-hydroxyl group. Other authors observed 
intramolecular interaction between 3-keto and 6-hy-
droxyl group leading to the 3,6-hemiketal ring, 20,21 and 
formation of 3,6-cyclic ethers by intramolecular dehy-
dration between 3- and 6-hydroxyl group.22,23 
Based on these independent findings we have de-
signed new azalide compounds with a unique tricyclic 
aglycone nucleus. Our synthetic strategy is shown in the 
Scheme 1. Starting bicyclic compounds 1-3 for both 
3,6-hemiketals 7-9 and 3,6-cyclic ethers 13-15 were 
prepared as reported in our recent paper.18 
After protection of 2'-hydroxyl group in 1-3 by a-
cetic anhydride, modified Pfitzner-Moffat oxidation24,25 
afforded intermediary 3-keto derivatives (not iso-lated). 
Reaction was carried out with 1-(3-dimethylamino-
propyl)-3-ethyl-carbodiimide hydrochloride, DMSO and 
pyridinium trifluoroacetate, followed by methanolysis 
of 2'-acetyl group to obtain tricyclic 3,6-hemiketals 7-9 
(Scheme 1). 
In the MS spectra of target compounds 7-9 the 
molecular ion (m/z) was in agreement with assigned 
structures. In the 13C NMR spectra of those compounds 
carbonyl carbamate signal was observed at ≈ 156 ppm.19 
The presence of 3,6-hemiketal ring in 7-9 was reflected 
in downfield shift of C-3 from 77.8 (1), 77.6 (2) and 
78.1 (3) ppm,18 to 103.4 (7), 103.3 (8) and 102.4 (9) 
ppm and downfield shift of C-6 atom from 71.5 (1), 
73.8 (2) and 73.6 (3) ppm18 to 84.4 (7), 84.4 (8) and 
83.5 (9) ppm. The signal for C-3 was consistently seen 
as a singlet. Further, a long range correlation in HMBC  
 
 
A. Fajdetić et al., Novel Tricyclic 15-membered Azalides 721 
Croat. Chem. Acta 82 (2009) 715. 
spectra between H-2 at ≈ 2.5 ppm and C-3 at ≈ 100 ppm 
confirmed the presence and location of hemiketal ring. 
The differences in chemical shifts between the starting 
compounds 1-3 and the new tricyclic hemiketals 7-9 
were observed for all carbon atoms included in newly 
formed ring (Table 1). 
Intramolecular dehydration of 3- and 6-hydroxyl 
groups afforded 3,6-cyclic ethers 13-15 (Scheme 1). 3-
Hydroxyl group was selectively activated as mesyl 
group and displaced by 6-alkoxy anion to give stable 5-
membered 3,6-cyclic ethers. 
An interesting observation was made in term of 
stereoselectivity of ether ring closure. Namely, this 
reaction was stereoselective when 12-OH function of 
starting 2 and 3 was alkylated. However, when starting 
compound has free 12-OH group (compound 1) two 
isomers 13a and 13b in a 1.8:1 ratio were obtained. 
Mass spectra of the intermediary 3-O-mesyl aza-
lides 10-12 reveal corresponding molecular ions, while 
IR spectra exhibited two characteristic bands at ≈ 1370 
and 1170 cm−1, for symmetric and asymmetric stret-
ching vibration of SO2 group. These compounds were 
used in the next step without further purification. 
For cyclic ethers 13-15 molecular ion (m/z) cor-
responds the proposed structure, whereas ether bond 
between C-3 and C-6 position was supported by 13C 
NMR chemical shifts (Table 3.). The significant down-
field shift of C-3 from 77.8 (1), 77.6 (2) and 78.1 (3) 
ppm,18 to 83.7 (13a), 83.0 (13b), 84.5 (14) and 83.3 (15) 
ppm and C-6 from 71.5 (1), 73.8 (2) and 73.6 (3) ppm18 
to 84.8 (13a), 84.5 (13b), 84.8 (14) and 83.1 (15) ppm 
confirmed that free hydroxyl groups are replaced by 
cyclic ether group.26 Chemical shifts of neighborhood 
atoms are in agreement with conformational reorganiza-
tions due to new formed ring. The most intriguing result 
represent low diastereoselectivity in cyclization of 7 to 
diastereomeric mixture 13a/13b, as compared to com-
pletely diastereoselective formation of 14 and 15. The 
1H NMR spectrum of isomeric mixture revealed two 
sets of signals in an approximate ratio 1.8:1 with both 
isomers having identical masses as indicated by HPLC-
MS. Assuming that 13a and 13b are epimers at position 
C-3, they had to be separated by chromatography and 
their NMR spectra analyzed in more details. Compari-
son of chemical shifts for 13a and 13b showed similari-
ty of major isomer 13a with 14 and 15. The main differ-
ences between 13a and 13b isomers are, as expected, in 
chemical shift values at 2, 3 and 4 positions of aglycone 
ring. Compound 13a exhibited signals for H-4, H-3 and 
H-2 at 2.09, 3.75 and 2.51 ppm, while for 13b signals 
for the same hydrogens appeared at 2.16, 4.12 and 2.74 
ppm, respectively (Table 3). Also there are significant 
differences in coupling between protons on C-2 and C-
3, 3JH-H 9.8 Hz for 13a, 14 and 15, as related to only 3.0 
Hz for 13b, indicating different torsion angle H-2/C-
2/C-3/H-3 (Table 4). In addition, the presence of NOE 
Table 4. Diagnostic vicinal coupling constants 3JH-H (Hz)  
for compounds 13a, 13b, 14 and 15 in CDCl3 
 13a 13b 14 15 
H2 / H3 9.8 3.0 9.7 9.7 
H3 / H4 7.4 8.8 7.7 7.3 
H4 / H5 4.1 4.0 4.9 4.9 
H10 / H11 6.0 5.8 5.9 5.9 
H13 / H14a 2.3 2.9 2.4 2.4 
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Scheme 1. Reagents and reaction conditions: a) Ac2O, NaHCO3, CH2Cl2, r.t., 4 h; b) DMSO, EDACxHCl, pyridinium trifluoroa-
cetate, CH2Cl2, 15 °C to r.t., 2.5 h; c) MeOH, r.t., overnight; d) (MeSO2)2O, pyridine, r.t., 4 h; e) 60 % NaH, DMF/THF (3:1), 0
°C, 4h; f) MeOH, r.t., overnight. 
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coupling between H-2 and H-10 protons in compounds 
13a, 14 and 15 and the lack of the same in 13b is in 
accordance with the proposed different spatial arrange-
ment around C-3 atom. Moreover, carefully observation 
of the model for 13a and 13b revealed unexpectedly 
large difference in proximity of H-2 and H-10 in these 
two diasteromers, which was in accordance with the 
presence of strong cross peak for 13a, 14 and 15 in the 
NOESY spectra. 
To confirm the participation of 6-OH group in 
both intramolecular interactions it was blocked as 6-O-
methyl ether in compound 19. Beckmann rearrangement 
of clarithromycin 9-(E)-oxime27 gave compound 16 
which was submitted to the preparation of 9a,11-cyclic 
carbamate structure 1719 followed by removal of cladi-
nose and 2'-acetylation18 (Scheme 2). 
As expected, when methoxy instead of free hy-
droxyl group is placed at position 6, oxidation of 3-
hydroxyl group gave 3-keto derivative 20, while dehy-
dration of 3-mesyl group led to 2,3-anhydro compound 
22 (Scheme 3). In the 13C NMR spectra of keto com-
pound 20 downfield shift of C-3 atom in carbonyl re-
gion (doublet at 77.6 ppm in 18 to singlet 207.1 ppm in 
20) was observed. Also disappearance of H-3 signal 
indicates formation of quarternary carbonyl group. Pro-
tons in environment of 3-keto functionality in 20 are 
shifted downfield (H-2; δ: 2.58→3.84, H-4; δ: 
2.12→3.20, H-5; δ: 3.56→4.36 (all δ values are in 
ppm)) as compared to 18. 
The structure of 2,3-anhydro compound 22 was 
confirmed by upfield shift of C-2 and C-3 atoms as 
compared to compound 18 (C-2; δ: 44.4→146.8, C-3; δ: 
77.6→122.9 (all δ values are in ppm)) as expected for 
double bonded C-atoms.26 1H NMR spectra also con-
firmed assumed structure, signals of H-2 (δ/ppm: 6.42 




Methods for the preparation of 15-membered azalides 
having tricyclic aglycone were described. Due to oxida-
tion conditions intramolecular ketalization of interme-
diary 3-keto derivative in 5-membered hemiketal ring 
was observed. Intramolecular Williamson-type of dis-
placement gave 5-membered ether derivatives. This was 
an interesting observation in term of stereoselectivity of 
ether ring closure. Namely, this reaction was stereose-




















































Scheme 2. Reagents and reaction conditions: a) CBzCl, NaHCO3, toluene, reflux, 4h; b) NaH, DMF, 0−5 C, 1h; c) 2 mol dm
−3
















































Scheme 3. Reagents and reaction conditions: a) DMSO, EDACxHCl, pyridinium trifluoroacetate, CH2Cl2, 15 °C to r.t., 2.5 h; b)
MeOH, r.t., overnight; c) (MeSO2)2O, pyridine, r.t., 4 h; d) 60 % NaH, DMF/THF (3:1), 0 °C, 4 h. 
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when starting compound has free 12-OH group two 
diastereomers were obtained. 
Although the compounds were not sufficient ac-
tive against MLS-resistant bacteria their rigid, stable 
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Sinteza i strukturna svojstva novih tricikličkih 15-eročlanih azilida 
Andrea Fajdetić, Gabrijela Kobrehel, Gorjana Lazarevski, Zorica Marušić-Ištuk i  
Stjepan Mutak 
GlaxoSmithKline istraživački centar Zagreb Ltd., Prilaz baruna Filipovića 29, 
10000 Zagreb, Hrvatska 
Polazeći iz 3-dekladinozil-9a,11-cikličkog karbamata 15-eročlanih azalida sintetizirani su napeti, triciklički 
aglikonski derivati. Intramolekularnom ketalizacijom intermedijarnog 3-keto derivata dobiven je peteročlani 
hemiketalni prsten dok su peteročlani eterski derivati dobiveni intramolekularnom Wiliamsonovom reakcijom. U 
slučaju 12-O-alkil derivata formiranje etera odvija se dijastereoselektivno, dok nesupstituirani derivat daje smjesu 
dijastereomera. Za potvrdu struktura novih, tricikličkih azalidnih derivate korištena je NMR analiza. 
